<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00335543</url>
  </required_header>
  <id_info>
    <org_study_id>IAGTDK-70-3046-Ho2</org_study_id>
    <secondary_id>CDR0000472206</secondary_id>
    <secondary_id>EU-20609</secondary_id>
    <secondary_id>ISRCTN78805636</secondary_id>
    <nct_id>NCT00335543</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery</brief_title>
  <official_title>Preoperative Chemoradiation in Locally Resectable Adenocarcinoma of Pancreatic Head Without Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Interdisziplinare Arbeitsgruppe Gastrointestinaler Tumore der Deutschen Krebsgesellschaft</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy
      together with radiation therapy before surgery may make the tumor smaller and reduce the
      amount of normal tissue that needs to be removed. Giving chemotherapy after surgery may kill
      any tumor cells that remain after surgery. It is not yet know whether giving chemotherapy
      together with radiation therapy before surgery is more effective than surgery alone in
      treating pancreatic cancer.

      PURPOSE: This randomized phase II trial is studying how well giving gemcitabine and cisplatin
      together with radiation therapy before surgery works compared to surgery alone in treating
      patients with localized pancreatic cancer that can be removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine whether neoadjuvant chemoradiotherapy comprising gemcitabine hydrochloride,
           cisplatin, and radiotherapy is better than immediate surgery, in terms of median
           survival, in patients with locally resectable adenocarcinoma of the pancreatic head.

      Secondary

        -  Compare 3-year survival rate in patients treated with these regimens.

        -  Compare R0 resection rate in these patients.

        -  Compare the rate of medium and high toxicity events in these patients.

        -  Compare the rate of complete and incomplete remission of the tumor as measured by
           radiographic imaging studies.

        -  Compare the rate of different regression gradings in resected tumor specimens.

        -  Compare the quality of life of these patients.

      OUTLINE: This is a prospective, randomized, controlled, open-label, multicenter study.
      Patients are stratified according to participating center and staging laparoscopy (yes vs
      no). Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV
           over 1 hour on days 1, 8, 22, and 29. Patients also undergo radiotherapy to the tumor
           and surrounding lymph nodes 5 days a week for 5 weeks followed by 3 more doses of
           radiotherapy directly to the tumor. Approximately 6 weeks after finishing
           chemoradiotherapy, patients with no evidence of disease progression undergo surgery to
           remove the tumor.

        -  Arm II: Patients undergo surgery to remove the tumor. After surgery, all patients
           receive adjuvant chemotherapy comprising gemcitabine hydrochloride IV over 30 minutes on
           days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of
           disease progression or unacceptable toxicity.

      Quality of life is assessed at baseline, at the end of chemotherapy and before surgery (arm
      I), and then at 6 weeks, 6 months, 12 months, and 24 months after surgery.

      After completion of study treatment, patients are followed every 3 months for 2 years and
      then at 3 years.

      PROJECTED ACCRUAL: A total of 254 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>3-year survival rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of medium and high toxicity events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete and incomplete remission of the tumor as measured by radiographic imaging studies</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of different regression gradings in resected tumor specimens</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life before, during, and after therapy</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">254</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed adenocarcinoma of the pancreatic head

               -  No tumors of the body or tail, as defined by a tumor lying between the left
                  border of the superior mesenteric vein and the left border of the aorta and/or
                  the left border of the aorta and the hilum of the spleen

          -  Locally resectable disease by CT scan

               -  Major vessels (e.g., portal vein, confluence of mesenteric and splenic vein,
                  superior mesenteric artery, celiac trunk, splenic artery, hepatic artery, or
                  superior mesenteric vein) maximally enclosed ≤ 180° by the tumor

          -  No infiltration of extrapancreatic organs except the duodenum

          -  No carcinoma of the ampulla of Vater

          -  No metastasis

          -  No peritoneal carcinoma

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 70-100%

          -  Creatinine clearance &gt; 70 mL/min

          -  Creatinine &lt; 1.5 mg/dL

          -  Platelet count &gt; 100,000/mm³

          -  No liver cirrhosis

          -  Not pregnant

          -  No New York Heart Association class III or IV heart disease

          -  No respiratory insufficiency

          -  No grade III or IV cardiac arrhythmias

          -  No pathology on EKG

          -  No other severe cardiopulmonary disease

          -  No HIV infection

          -  No other disease that renders the patient unsuitable for one treatment option

          -  No other malignancy except nonmelanoma skin cancer, carcinoma in situ of the cervix,
             or other cancer for which the patient was treated with surgery only and has been in
             complete remission for ≥ 10 years

        PRIOR CONCURRENT THERAPY:

          -  At least 3 months since prior participation in another clinical trial

          -  No prior or other concurrent treatment for carcinoma of the pancreas
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W. Hohenberger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitaet Erlangen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Innsbruck Universitaetsklinik</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus - Universitatskliniken</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Roessle Comprehensive Cancer Center - Charite Campus Buch</name>
      <address>
        <city>Berlin</city>
        <zip>D-13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knappschaft Krankenhaus</name>
      <address>
        <city>Bochum</city>
        <zip>D-44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIAKO Ev. Diakonie Krankenhaus gGmbH</name>
      <address>
        <city>Bremen</city>
        <zip>D-28239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Dresden - Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <zip>D-01008</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>D-91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arbeitsgruppe Lebermetastasen und Tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik am Eichert</name>
      <address>
        <city>Goeppingen</city>
        <zip>D-73035</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chirurgische Universitaetsklinik</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>D-04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>D-39130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen - Grosshadern Campus</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nuernberg - Klinikum Nord</name>
      <address>
        <city>Nuremberg</city>
        <zip>D-90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>D-93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Golcher H, Brunner T, Grabenbauer G, Merkel S, Papadopoulos T, Hohenberger W, Meyer T. Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy. Eur J Surg Oncol. 2008 Jul;34(7):756-64. doi: 10.1016/j.ejso.2007.11.012. Epub 2008 Jan 10.</citation>
    <PMID>18191528</PMID>
  </results_reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2006</study_first_submitted>
  <study_first_submitted_qc>June 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2006</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>stage I pancreatic cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

